GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.

Legislative efforts and a Trump administration initiative could lead in the near future to Medicare beneficiary access to ...

The "no cost" surgical benefit signifies the State Health Plan will cover the surgical cost for members that they normally ...

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss.

Trump administration eyes Medicare and Medicaid coverage for weight loss drugs like Wegovy and Ozempic in a five-year pilot ...

The stock of Eli Lilly and Company was up in early trading on Aug. 4 amid reports that Medicare may soon cover its weight-loss medications. This could significantly boost the affordability of Eli ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Some obese Americans on Medicare and Medicaid could get access to expensive weight loss drugs under a five-year experiment ...